Gastroesophageal Cancer | Disease Landscape & Forecast | G7 | 2025
Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market growth. Multimodal therapy—combining HER2-targeted agents, checkpoint inhibitors, and chemotherapy—has become the standard for HER2- and PD-L1-positive disease. Recently, Imfinzi (AstraZeneca) entered the perioperative setting for gastric cancer, while Vyloy (Astellas), the first-in-class claudin-18.2 inhibitor, is reshaping first-line treatment for HER2-negative patients. In later lines, emerging agents targeting biomarkers such as TROP-2 and B7-H3 are expected to broaden therapeutic options. With a strong late-phase pipeline, additional approvals—such as Ziihera (Jazz Pharmaceuticals)—are anticipated during the forecast period.
Questions answered
- How is gastroesophageal cancer segmented by subpopulation, and what is the size of the drug-treatable and drug-treated populations?
- What are the key current therapies for gastroesophageal cancer, and how are they positioned in the treatment algorithm?
- Which emerging therapies are the most promising, and how will they shape the future of the gastroesophageal cancer therapy market?
- What are the drivers of and constraints on the gastroesophageal cancer therapy market, and how will the market evolve over the forecast period?
Content highlights
Geography: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by stage of disease, histology, HER2 status, and line of therapy
Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2034, segmented by brands / generics / biosimilars and drug-treatable populations
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:
- Optimize your long-term disease and development strategy.
- Quantify market potential for your pipeline assets and those of your competitors.
- Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
- Gauge the commercial outlook and impact of key market events.
